Nathaniel D. Collins

Statistics

Publications

Citations

1.3K

H-Index

Active since

1998

Affiliations

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute(Current)

The Ohio State University

Washington University in St. Louis

Bristol-Myers Squibb (United States)

Boehringer Ingelheim (United States)

Nathaniel D. Collins is an author at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute specializing in life sciences, pharmacology, and virology.

Publications per year

1998–2021

Publications

Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium

Frank Dieterle, Frank D. Sistare, Federico Goodsaid et al. · Nature Biotechnology · 2010 · 406 citations

Medicine, Nephrology, Precision Medicine +13

Selective Ablation of Human T-Cell Lymphotropic Virus Type 1 p12I Reduces Viral Infectivity In Vivo

Nathaniel D. Collins, Garret C. Newbound, Björn Albrecht et al. · Blood · 1998 · 159 citations

Life Sciences, Immunology, Molecular Biology +13

Functional Role of pX Open Reading Frame II of Human T-Lymphotropic Virus Type 1 in Maintenance of Viral Loads In Vivo

Joshua T. Bartoe, Björn Albrecht, Nathaniel D. Collins et al. · Journal of Virology · 2000 · 128 citations

Life Sciences, Genetics, Molecular Biology +9

Towards consensus practices to qualify safety biomarkers for use in early drug development

Frank D. Sistare, Frank Dieterle, Sean P. Troth et al. · Nature Biotechnology · 2010 · 121 citations

Pharmacy, Pharmacology, Regulatory Pharmacy +16

Human T-Lymphotropic Virus Type 1 Open Reading Frame I p12<sup>I</sup>Is Required for Efficient Viral Infectivity in Primary Lymphocytes

Björn Albrecht, Nathaniel D. Collins, Mark T. Burniston et al. · Journal of Virology · 2000 · 91 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +13

1–5 of 17